ACELYRIN INC (SLRN) Stock Overview
USA - NASDAQ:SLRN - US00445A1007 - Common Stock
SLRN Key Statistics, Chart & Performance
The current stock price of SLRN is 2.27 USD. In the past month the price decreased by -2.99%. In the past year, price decreased by -45.04%.
SLRN Latest News, Press Relases and Analysis
SLRN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About SLRN
Company Profile
ACELYRIN, Inc. operates as a biopharma company. The company is headquartered in Agoura Hills, California and currently employs 83 full-time employees. The company went IPO on 2023-05-05. The firm is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The firm has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The firm is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.
Company Info
ACELYRIN INC
4149 Liberty Canyon Rd.
Agoura Hills CALIFORNIA US
Employees: 93
Phone: 18054564393
ACELYRIN INC / SLRN FAQ
What does ACELYRIN INC do?
ACELYRIN, Inc. operates as a biopharma company. The company is headquartered in Agoura Hills, California and currently employs 83 full-time employees. The company went IPO on 2023-05-05. The firm is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The firm has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The firm is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.
What is the stock price of ACELYRIN INC today?
The current stock price of SLRN is 2.27 USD. The price increased by 1.79% in the last trading session.
Does SLRN stock pay dividends?
SLRN does not pay a dividend.
What is the ChartMill technical and fundamental rating of SLRN stock?
SLRN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy SLRN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SLRN.
What is the employee count for SLRN stock?
ACELYRIN INC (SLRN) currently has 93 employees.
What is the next earnings date for SLRN stock?
ACELYRIN INC (SLRN) will report earnings on 2025-08-11.
SLRN Technical Analysis
SLRN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SLRN. While SLRN has a great health rating, there are worries on its profitability.
SLRN Financial Highlights
Over the last trailing twelve months SLRN reported a non-GAAP Earnings per Share(EPS) of -2.99. The EPS decreased by -15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.52% | ||
| ROE | -65.94% | ||
| Debt/Equity | 0 |
SLRN Forecast & Estimates
8 analysts have analysed SLRN and the average price target is 8.16 USD. This implies a price increase of 259.47% is expected in the next year compared to the current price of 2.27.